Regeneron Pharmaceuticals
Présence
Regeneron Pharmaceuticals fait partie des...
Regeneron Pharmaceuticals est une société cotée sous le symbole boursier REGN (US).
Elles sont en:
- Pharmacie50%
- Biotechnologie50%
Acquisition, funding and merger involving Regeneron Pharmaceuticals.
- Regeneron Pharmaceuticals a acquis Checkmate Pharmaceuticals (publié le 29 novembre 2022).
- Regeneron Pharmaceuticals has announced the acquisition of Checkmate Pharmaceuticals (publié le 31 mai 2022).
Dirigeants
Voir l'organigramme avec ses 88 principaux dirigeants
Biographies les plus recherchées chez Regeneron Pharmaceuticals
- Leonard Schleifer, President, Chief Executive Officer, Director
- Huda Zoghbi, Director
- Marc Tessier-Lavigne, Director
Changements de dirigeants chez Regeneron Pharmaceuticals
- Robert Landry, Executive Vice President, Finance and Chief Financial Officer, partira en retraite en févr. 2024 (publié le 11 septembre 2023).
- Chris Fenimore qui est Senior Vice President and Controller, sera promu Chief Financial Officer en févr. 2024 (publié le 11 septembre 2023).
Créer une alerte
pour suivre les mouvements de dirigeants chez Regeneron Pharmaceuticals.
Pharmacie
Regeneron Pharmaceuticals a 1 867 concurrents dont Pfizer (Etats—Unis), Sanofi (France) et Johnson & Johnson (Etats—Unis).
Actualités en fusion/acquisition en Pharmacie.
- AstraZeneca has announced the acquisition of Fusion Pharma (publié le 23 mars 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publié le 19 mars 2024).
- Frontier Medicines vient d'annoncer une levée de fonds de 80 millions de dollars. (publié le 27 février 2024).
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par Regeneron Pharmaceuticals
- CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Atopic Dermatitis | Regeneron Pharmaceuticals Inc.
- https://newsroom.regeneron.com/node/24391/pdf
- https://newsroom.regeneron.com/node/24386/pdf
- Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb®) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus) | Regeneron Pharmaceuticals Inc.
- Dupixent® (dupilumab) Significantly Reduced Severe Asthma Attacks in Children and is the Only Biologic to Demonstrate Improvement in Children's Lung Function in a Randomized Phase 3 Trial | Regeneron Pharmaceuticals Inc.
- Regeneron to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2020 | Regeneron Pharmaceuticals Inc.
- Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients | Regeneron Pharmaceuticals Inc.
- Late-breaking ESMO Presentation Shows Libtayo® (cemiplimab) Monotherapy Increases Overall Survival in First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50% | Regeneron Pharmaceuticals Inc.
- Press Releases | Regeneron Pharmaceuticals Inc.
- Positive Pivotal Data for Libtayo® (cemiplimab) Monotherapy in Locally Advanced Basal Cell Carcinoma Featured as a Late-breaking Presentation at ESMO | Regeneron Pharmaceuticals Inc.
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Regeneron Pharmaceuticals
- Regeneron Pharmaceuticals sur Wikipédia, Google News & Yahoo Finance en 1-click
- Regeneron Pharmaceuticals sur LinkedIn, Twitter & YouTube en 1-click
